Preparation and characterization of biodegradable polyhydroxybutyrate-co-hydroxyvalerate/polyethylene glycol-based microspheres

Abstract : The in vivo effectiveness of biomolecules may be limited by their rapid diffusion in the body and short half-life time. Encapsulation of these biomolecules allows protecting them against degradation and ensuring a controlled release over time. In this work, the production of polyhydroxybutyrate-co-hydroxyvalerate/polyethylene glycol-based microspheres loaded with heparin by double emulsion-solvent evaporation is investigated. Significant improvements are achieved after blending PHB-HV microspheres with PEG. First of all, an important decrease of the initial burst effect is ensured. Moreover, lower degradation of the microspheres is observed after 30 days in the release medium. Finally, the release rate could be controlled using different PEG molecular weights and concentrations. A toxic effect of PHB-HV 30% PEG 1100 g mol(-1) microspheres is observed whereas PHB-HV and PHB-HV 30% PEG 10,000 g mol(-1) microspheres are not toxic. These microspheres seem to be most suited for further tissue engineering applications. The effectiveness of direct PEG blending to PHB-HV is proved, limiting the use of chemical reagents for PHB-HV/PEG copolymer synthesis and steps for chemical reagents removal from the copolymer. (C) 2016 Elsevier B.V. All rights reserved.
Type de document :
Article dans une revue
International Journal of Pharmaceutics, Elsevier, 2016, 513 (1-2), pp.49-61. 〈10.1016/j.ijpharm.2016.08.066〉
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-01454787
Contributeur : Eric Berton <>
Soumis le : vendredi 3 février 2017 - 09:13:41
Dernière modification le : jeudi 25 octobre 2018 - 10:34:03

Identifiants

Collections

Citation

Alexandre Monnier, Charlotte Rombouts, Dania Kouider, Imad About, Hatem Fessi, et al.. Preparation and characterization of biodegradable polyhydroxybutyrate-co-hydroxyvalerate/polyethylene glycol-based microspheres. International Journal of Pharmaceutics, Elsevier, 2016, 513 (1-2), pp.49-61. 〈10.1016/j.ijpharm.2016.08.066〉. 〈hal-01454787〉

Partager

Métriques

Consultations de la notice

59